non small cell lung cancer

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
April, 2025
April 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  

non small cell lung cancer
Mar 26, 2025, 16:35 | Drugs
MARIPOSA trial results presented at ELCC25 - BREAKING from Paris
MARIPOSA reports OS benefit with amivantamab–lazertinib vs osimertinib monotherapy! This year, the European Lung Cancer…
Mar 18, 2025, 18:16 | Insight
FDA grants accelerated approval to Zenocutuzumab-zbco - The Babak Lab
The Babak Lab shared a post on LinkedIn: "FDA Grants Accelerated Approval to Zenocutuzumab-zbco (Bizengri).…
Mar 16, 2025, 15:00 | Science
Jarushka Naidoo: Brentuximab Vedotin and Pembro in PD-1-Pretreated NSCLC and Melanoma
Jarushka Naidoo, Full Professor and Consultant Medical Oncologist at Royal College of Surgeons in Ireland,…
Mar 16, 2025, 11:09 | Science
Umberto Malapelle: Costs of biomarker testing in advanced non-small cell lung cancer
Umberto Malapelle, Associate Professor at the School of Medicine at the University of Naples Federico,…
Mar 15, 2025, 15:34 | Science
Alper Topal: The efficacy and safety profile of crizotinib treatment in patients with metastatic NSCLC
Alper Topal, Medical Oncologist in the Turkish Armed Forces, shared a post on X about…
Mar 15, 2025, 15:24 | Blog
How long can you live with lung cancer without treatment? - Cizzle Bio
Cizzle Bio shared a post on LinkedIn: "How Long Can You Live With Lung Cancer…
Mar 14, 2025, 13:20 | Science
David Planchard: Unparalleled benefit of Osimertinib for EGFR-mutated advanced NSCLC
David Planchard, Thoracic Oncologist and Professor at the University Paris Saclay, shared an article by…
Mar 11, 2025, 13:12 | Science
Patrick Forde: PD-1 VEGF bispecific doubles PFS in 1st line advanced NSCLC
Patrick Forde, Professor at Johns Hopkins University and Co-Director of the Division of Upper Aerodigestive…
Mar 6, 2025, 18:38 | Insight
Vun-Sin Lim: 10 Most Cited 2024 Articles in the Journal of Thoracic Oncology
Vun-Sin Lim, Managing Editor of the Journal of Thoracic Oncology, shared a post on LinkedIn:…
Mar 6, 2025, 10:22 | Science
Yuji Uehara: TKIs for non-small cell lung cancer with EGFR exon 19 insertions
Yuji Uehara, Medical Oncologist at National Cancer Center Japan, shared a post on X about…
Mar 5, 2025, 13:46 | Career
Keith Kerr Receives the 2025 Heine H. Hansen Award
On March 4, 2025, ESMO announced that Prof. Keith Kerr has been awarded the 2025…
Mar 5, 2025, 11:23 | Science
Plasma ctDNA Kinetics Predicts Therapy Response in Advanced NSCLC - International Society of Liquid Biopsy
International Society of Liquid Biopsy shared an article by Luís F Leite da Silva, et…
Mar 4, 2025, 05:32 | Science
Erick Saldanha: Proud to wrap up February with 2 publications
Erick Saldanha, Medical Oncologist and Postdoctoral Clinical Fellow at Princess Margaret Cancer Centre, shared a…
Mar 3, 2025, 15:56 | Science
Selpercatinib in RET Fusion-Positive NSCLC by Oliver Gautschi et al.
A paper by Oliver Gautschi et al. was published in the Journal of Clinical Oncology,…
Mar 3, 2025, 12:52 | Science
5 papers about Lung Cancer suggested by Stephen Liu
Stephen Liu, Director of Thoracic Oncology and Head of Developmental Therapeutics at the Georgetown Lombardi…
Mar 3, 2025, 11:31 | Insight
Yuji Uehara: Morning immuno-chemotherapy nearly doubled survival in NSCLC
Yuji Uehara, Medical Oncologist at National Cancer Center Japan, shared a post on X about…
Mar 3, 2025, 10:24 | Blog
ASCO's new living guideline update for Stage IV NSCLC with Driver Alterations
American Society of Clinical Oncology (ASCO) shared a post on LinkedIn: "The American Society of…
Mar 2, 2025, 06:55 | Science
5 papers about Lung Cancer suggested by Stephen Liu
Stephen Liu, Director of Thoracic Oncology and Head of Developmental Therapeutics at the Georgetown Lombardi…
Mar 1, 2025, 12:41 | Science
Gilberto Lopes: ctDNA decrease and clearance are associated with PFS and OS in lung cancer
Gilberto Lopes, Chief of the medical oncology division and professor of clinical medicine at the…
Feb 28, 2025, 14:43 | Science
Drew Moghanaki: Why there is a desire to deliver SBRT to ultra-central tumors
Drew Moghanaki, Professor and Chief of Thoracic Oncology at the Department of Radiation Oncology at…
Feb 27, 2025, 13:45 | Science
Alessandra Vaccaro: What can we do as a community to improve clinical outcomes?
Alessandra Vaccaro, Postdoctoral fellow at MD Anderson Cancer Center, shared her recent article on LinkedIn:…
Feb 26, 2025, 01:39 | Science
5 papers about Lung Cancer suggested by Stephen Liu
Stephen Liu, Director of Thoracic Oncology and Head of Developmental Therapeutics at the Georgetown Lombardi…
Feb 24, 2025, 12:46 | Science
5 papers about Lung Cancer suggested by Stephen Liu
Stephen Liu, Director of Thoracic Oncology and Head of Developmental Therapeutics at the Georgetown Lombardi…
Feb 23, 2025, 18:32 | Science
5 papers about Lung Cancer suggested by Stephen Liu
Stephen Liu, Director of Thoracic Oncology and Head of Developmental Therapeutics at the Georgetown Lombardi…
Feb 23, 2025, 01:42 | Science
5 papers about Lung Cancer suggested by Stephen Liu
Stephen Liu, Director of Thoracic Oncology and Head of Developmental Therapeutics at the Georgetown Lombardi…
Feb 22, 2025, 15:54 | Blog
Patrick Forde: Great day for lung cancer care
Patrick Forde, Professor at Johns Hopkins University and Co-Director of the Division of Upper Aerodigestive…
Feb 18, 2025, 19:35 | Science
Elizabeth McKenna: High Glucose Contribution to the Non–Small Cell Lung Cancer Patients
Elizabeth McKenna, Executive Director of Cancer Discovery at the American Association for Cancer Research, shared…
Feb 6, 2025, 10:51 | Blog
Start a conversation with your patients about the importance of biomarker testing - LUNGevity Foundation
LUNGevity Foundation shared a post on LinkedIn: "Healthcare providers - testing for all clinically recommended…
Feb 4, 2025, 09:59 | Science
Gustavo Viani: Immunotherapy + cCRT in Stage III NSCLC
Gustavo Viani, Professor of Radiation Oncology at Ribeirão Preto Medical School, shared an article by…
Jan 30, 2025, 06:15 | Insight
NSCLC treated with EGFR inhibitors - EGFR Resisters
EGFR Resisters shared a post on X about a recent paper by Otto Manninen et…
Jan 29, 2025, 08:15 | Science
Comprehensive molecular profiling of squamous non-small cell lung cancer
Akhil Santhosh, Medical Oncologist at AIIMS Delhi, shared an article by Joshua E. Reuss on…
Jan 27, 2025, 09:42 | Science
Giannis Mountzios: Are we treating our NSCLC patients with the optimal dose and duration of immunotherapy?
Giannis Mountzios, Director of the 4th Oncology Department and Clinical Trials Unit at Henry Dunant…
Jan 20, 2025, 16:03 | Science
Amy Moore: Biomarker testing can help identify actionable mutations in patients with squamous NSCLC
Amy Moore, Vice President of Global Engagement and Patient Partnerships at LUNGevity Foundation, shared a…
Jan 20, 2025, 14:16 | Insight
Amy Moore: Ensuring that all patients benefit from recent scientific advances in lung cancer
Amy Moore, Vice President of Global Engagement and Patient Partnerships at LUNGevity Foundation, shared a…
Jan 19, 2025, 14:12 | Science
Khalil Choucair: Potential biomarkers of IO-therapy in patients of extremes of age
Khalil Choucair, Chief Fellow of Hematology & Oncology at Karmanos Cancer Institute, reshared a post…
Jan 17, 2025, 14:52 | Science
Marcelo Negrao: Co-mutations and transcriptional signatures in non-small cell lung cancer patients
Marcelo Negrao, Assistant Professor of Medical Oncology at MD Anderson Cancer Center, shared his recent…
Jan 13, 2025, 04:50 | Insight
Hidehito Horinouchi: Potential long-term clinical benefit from CheckMate 816
Hidehito Horinouchi, Assistant Chief of the National Cancer Center Hospital, shared a post on X…
Jan 12, 2025, 19:21 | Blog
Avrum Spira: Expanded collaboration with Ankyra Therapeutics for local immunotherapy in NSCLC
Avrum Spira, Global Head of the Interventional Oncology R&D Unit at Johnson and Johnson, shared…
Jan 12, 2025, 12:56 | Insight
Tom Cavanaugh: Inspired by the topline results from the Phase 3 MARIPOSA study
Tom Cavanaugh, Company Group Chairman at Johnson and Johnson Innovative Medicine, shared a post on…
Jan 10, 2025, 17:01 | Insight
Biagio Ricciuti: Datopotamab Deruxtecan in Advanced/Metastatic NSCLC by Jacob Sands et al.
Biagio Ricciuti, Thoracic Medical Oncologist at the Dana-Farber Cancer Institute, shared a post on X about…
Jan 9, 2025, 11:42 | Insight
Hidehito Horinouchi: ATORG expert consensus statement on the peri-operative management of NSCLC
A recent paper by Stephanie Saw, Medical Oncologist at National Cancer Centre Singapore, was mentioned…
Jan 8, 2025, 12:38 | Blog
Antonio Passaro: Major Breakthrough Announced - MARIPOSA Study Results
Antonio Passaro, Medical Oncologist and a Medical Director with High Specialization Assignment at the European…
Jan 7, 2025, 14:28 | Science
Valuable insights from a new article on Unresectable Stage IIIA/IIIB NSCLC - IU Simon Comprehensive Cancer Center
IU Simon Comprehensive Cancer Center shared a post on LinkedIn about a recent paper by…
Jan 7, 2025, 09:46 | Science
Glecirasib in KRASG12C-mutated non-small cell lung cancer by Yuankai Shi et al.
Yakup Ergün, Medical Oncologist at Antalya City Hospital, shared a post on X about a…
Jan 3, 2025, 21:19 | Science
Luis Raez: We have a lot of survivors on osimertinib alone that will need second-line therapy in the future
Luis Raez, Medical Director and Chief Scientific Officer at Memorial Cancer Institute, shared a post…
Dec 29, 2024, 10:21 | Insight
Existing biomarkers predicting ICI treatment response in advanced NSCLC
JAMA Oncology shared a post on X: “A deep learning AI model showed improved accuracy…
Dec 25, 2024, 09:42 | Science
The association of oncogene driver mutations with recurrence and survival in stage I NSCLC
Clinical Lung Cancer shared an article by Daniel M. Libby on X: "Explore a new…
Dec 20, 2024, 14:19 | Science
Ravi Parikh: Predicting immunotherapy response in non-small cell lung cancer
Ravi Parikh, Director of Human-Algorithm Collaboration Lab at Winship Cancer Institute of Emory University, shared…
Dec 19, 2024, 12:01 | Insight
Remon Jordi Discusses Advances in Thoracic Oncology at ESMO Asia 2024
Mediamedic shared a post on LinkedIn: “ESMO Asia 2024, Jordi Remon Masip Highlights Key Thoracic…
Dec 17, 2024, 16:18 | Insight
Update on U.S. Regulatory Review of Subcutaneous Amivantamab
Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) has issued a…
Dec 12, 2024, 13:14 | Blog
Razelle Kurzrock: Targeting NRg1 fusions
Razelle Kurzrock, Associate Director of Clinical Research for the Medical College of Wisconsin Cancer Center,…
Dec 11, 2024, 15:48 | Insight
Tumor Methylation Burden in Non-Small Cell Lung Cancer: A New Way of Thinking About Epigenetics
"One of the emerging biomarkers in lung cancer that is gaining attraction is Tumor Methylation…
Dec 11, 2024, 10:30 | Insight
David D. W. Lee: Proud to be a part of the Pan-Asian adapted ESMO Clinical Practice Guideline
David D. W. Lee, Consultant Clinical Oncologist at the University of Malaya Medical Centre and…
Dec 9, 2024, 14:27 | Insight
Sanjay Popat: The Pan-Asian adapted ESMO Clinical Practice Guidelines for Oncogene Addicted Metastatic NSCLC
Sanjay Popat, Professor at The ICR and Thoracic Oncologist at The Royal Marsden NHS Foundation Trust,…
Dec 8, 2024, 04:47 | Insight
Exciting developments in the management of unresectable stage III EGFR NSCLC
Aakash Desai, Assistant Professor and Associate Director at UAB O'Neal Comprehensive Cancer Center, shared an…
Dec 5, 2024, 11:01 | Insight
FDA Grants Accelerated Approval to Zenocutuzumab-zbco for NSCLC and Pancreatic Adenocarcinoma
On December 4, 2024, the U.S. Food and Drug Administration (FDA) granted accelerated approval for…
Nov 26, 2024, 15:12 | Insight
Management of Stage III Non–Small Cell Lung Cancer
Jame Abraham, Chairman of the Department of Hematology and Medical Oncology at Cleveland Clinic, shared…
Nov 23, 2024, 12:01 | Blog
Aakash Desai: Bridging the gap between clinical advancements and real-world application
Aakash Desai, Associate Director and Assistant Professor at UAB O'Neal Comprehensive Cancer Center, shared a…
Nov 21, 2024, 12:57 | Insight
Navneet Singh: Molecular testing in all stages of NSCLC
Navneet Singh, A Thoracic Medical Oncologist and a Professor at PGIMER, shared an article on…
Nov 20, 2024, 15:19 | Insight
Eric Lim: Immunotherapy - before, after or both?
Eric Lim, Professor of Thoracic Surgery at Royal Brompton Hospital, shared his recent article on…
Nov 16, 2024, 10:00 | Blog
The IASLC Advanced Radiation Technology Subcommittee's webinar on radiation oncology for locally advanced non-small cell lung cancer
IASLC posted on X: "The IASLC Advanced Radiation Technology Subcommittee of the Multidisciplinary Clinical Science…
Nov 14, 2024, 13:11 | Blog
American Society of Clinical Oncology's new living guideline update for Stage IV NSCLC with Driver Alterations
American Society of Clinical Oncology (ASCO) shared a post on LinkedIn: "Check out our new…
Nov 1, 2024, 17:46 | Blog
Hidehito Horinouchi: Early Stage NSCLC at ACLC24 session
Hidehito Horinouchi, Assistant Chief of the National Cancer Center Hospital, shared a post on X:…
Oct 29, 2024, 21:00 | Positive
Steven O'Day: At the Forefront of Immunotherapy
Dr. Steven O'Day, an immunotherapy pioneer and medical oncologist, is the Chief Medical Officer at…
Oct 25, 2024, 16:34 | Insight
Three decades of pioneering in Immune Oncology - Agenus
Agenus Inc. is a biopharmaceutical company and a prominent leader in the field of immuno-oncology,…
Oct 21, 2024, 13:21 | Blog
Rahul Gosain: US FDA approval of Durvalumab for resectable NSCLC with Mara Antonoff and Sandip Patel
Rahul Gosain shared a post on LinkedIn: ''Lung Cancer: We speak about the US FDA…
Oct 20, 2024, 11:01 | Blog
Alectinib for ALK-positive non-small-cell lung cancer - NICE
NICE - National Institute for Health and Care Excellence shared a post on X: "A targeted…
Oct 19, 2024, 15:57 | Insight
FDA Approves Tumor Treating Fields for Advanced NSCLC: Insights from the LUNAR Trial
The FDA has approved tumor treating fields (TTFields; Optune Lua) in combination with docetaxel or…
Oct 15, 2024, 12:59 | Blog
Brendon Stiles: We owe it to our patients with EGFR mutations
Brendon Stiles, Professor and Chief, Thoracic Surgery and Surgical Oncology, Montefiore Health System shared a post on…
Oct 13, 2024, 10:59 | Insight
Alessandro Di Federico: Honored to have our work highlighted in this months issue of Annals of Oncology
Alessandro Di Federico shared a post by Annals of Oncology on X, adding: "Honored to have…
Oct 11, 2024, 19:32 | Insight
Hung Trinh: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors
Hung Trinh shared a post on LinkedIn: “CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.…
Oct 9, 2024, 15:23 | Blog
Upal Basu Roy: How immune cells can be engineered to target EGFR+ NSCLC
Upal Basu Roy, Executive Director of Research at LUNGevity Foundation, shared about a Facebook Live…
Oct 6, 2024, 14:01 | Insight
MD Anderson Research Highlights
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in…
Oct 5, 2024, 23:43 | Insight
MD Anderson Research Highlights for the 2024 World Conference on Lung Cancer
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent…
Oct 2, 2024, 14:41 | Insight
Stephen Liu: Phase Ib study of naporafenib with rineterkib or trametinib in NSCLC
Stephen Liu shared a post on X about a recent paper by David Planchard et…
Sep 24, 2024, 16:52 | Blog
Assessment of the safety and efficacy of Balstilimab in combination with Botensilimab for NSCLC - Immune Oncology Research Institute
Immune Oncology Research Institute shared a post on LinkedIn: ''Assessment of the safety and efficacy…
Sep 23, 2024, 20:18 | Blog
Antonio Passaro: Honored to have presented the SOHO-02 clinical trial
Antonio Passaro shared a post on LinkedIn: "I am truly honored to have presented the…
Sep 20, 2024, 14:04 | Dialogues
ASCO24 Updates: Jonathan Nascimento Priantti on osimertinib's Efficacy in Uncommon EGFR Mutations | OncoDaily
The American Society of Clinical Oncology (ASCO) Annual Meeting is one of the largest and most…
Sep 17, 2024, 15:07 | Blog
Stephen V Liu: Data from ARROS-1 study of NVL-520 in ROS1 NSCLC
Stephen V Liu shared a post on X: ''Benjamin Besse presents data from ARROS-1 study…
Sep 13, 2024, 08:23 | Blog
Vivek Subbiah: HER2 mutant NSCLC now has an oral TKI option without ILD
Vivek Subbiah shared a post by Chul Kim, on X, adding: ''Wow! HER2 mutant non-small…
Sep 11, 2024, 16:13 | Insight
RYBREVANT plus LAZCLUZE versus osimertinib in EGFR-mutated advanced lung cancer
New longer-term data from the MARIPOSA study confirm superior outcomes of chemotherapy-free RYBREVANT plus LAZCLUZE regimen compared…
Sep 11, 2024, 13:54 | Blog
Noemi Reguart: Presidential Phase 3, Ivonescimab vs Pembrolizumab for PD-L1+ advanced NSCLC
Noemi Reguart shared a post on X: ''WCLC24 Presidential. Phase 3 Ivonescimab (AK112) versus Pembrolizumab…
Sep 10, 2024, 13:45 | Societies
Rami Manochakian's key highlights from WCLC24
WCLC is a major international event focused on the latest advancements in lung cancer research,…
Sep 4, 2024, 11:52 | Blog
Frequently asked questions about biomarker testing in NSCLC - LUNGevity Foundation
LUNGevity Foundation shared a post on X: ''Looking for answers on biomarker testing in non-small…
Sep 4, 2024, 05:57 | Insight
Maria Lucia Reale: MET exon 14 skipping mutations in NSCLC
Maria Lucia Reale, Medical Oncologist at Vito Fazzi Hospital Company, shared on X: “Just out…
Sep 2, 2024, 08:32 | Insight
Drew Moghanaki: Single fraction lung SBRT has become my go-to for medically inoperable stage I NSCLC
Drew Moghanaki shared a post on X about a paper by Gregory Videtic et al.…
Sep 2, 2024, 03:41 | Insight
FDA Grants Zongertinib Breakthrough Therapy Designation in HER2-Mutant NSCLC
The FDA has recently granted Zongertinib, a HER2-specific tyrosine kinase inhibitor (TKI), Breakthrough Therapy Designation…
Aug 29, 2024, 17:43 | Insight
FDA’s latest approvals summarized by Samuel Hume
Samuel Hume, Researcher at the University of Oxford, recently shared on X: “The FDA approved 4…
Aug 29, 2024, 16:56 | Insight
Stephen Liu: Overview of outcomes with 1L osimertinib
Stephen Liu shared a post on X about a recent paper by Kageaki Watanabe et…
Aug 28, 2024, 03:51 | Insight
Article of the day, suggested by the Immune Oncology Research Institute
Immune Oncology Research Institute shared a post on LinkedIn: "Article of the day! Suggest by…
Aug 26, 2024, 21:42 | Blog
Tanja Obradovic: Interesting update at ESMO 2024 on cancer-induced cachexia as PhII trial of ponsegromab
Tanja Obradovic posted on LinkedIn: “Interesting update will come at ESMO 2024 on possible option…
Aug 26, 2024, 21:24 | Blog
Tanja Obradovic: Can we expect new EGFR TKI to surpass osimertinib in primary tumor and intracranial progression of NSCLC
Tanja Obradovic posted on LinkedIn: “Can we expect new EGFR TKI that can significantly surpass…
Aug 25, 2024, 17:20 | Dialogues
Beyond The Cancer Diagnosis: Dialogue with Sonia Amin Thomas, Hosted By Adrian Pogacian
For this latest episode of ‘Beyond the Cancer Diagnosis’, Adrian Pogacian debates the Psychological Dimension of NSCLC (Non-Small Cell…
Aug 22, 2024, 14:00 | Insight
Jarushka Naidoo: Phase II Lazertinib in EGFR+ NSCLC with CNS disease
Jarushka Naidoo shared a post on X: “Phase II Lazertinib in EGFR+ NSCLC with CNS disease,…
Aug 20, 2024, 13:48 | Insight
Stephen Liu: So many great WCLC24 sessions to choose from
Stephen Liu shared a post on X: “So many great WCLC24 sessions to choose from.…
Aug 19, 2024, 11:40 | Insight
Brian Shields: Pfizer's CROWN study was a highlight of ASCO24
Brian Shields, Creator of KOL Pulse AI, shared on LinkedIn: “Pfizer's CROWN study was a…
Aug 17, 2024, 15:38 | Blog
Forging a Future For Precision Medicine - Lung MAP
Lung MAP shared a post on X: "The Lung-MAP precision medicine trial in non-small cell…
Aug 17, 2024, 08:15 | Blog
Mahadi Baig: U.S. FDA granted priority review of Johnson and Johnson Innovative Medicine's subcutaneous treatment for patients with EGFR-mutated NSCLC
Mahadi Baig, Global Medical Head, Amivantamab at Johnson and Johnson, shared a post on LinkedIn:…
Aug 13, 2024, 19:38 | Insight
Aakash Desai: MYC IHC could be crucial in tailoring immunotherapy approaches in NSCLC
Aakash Desai, Assistant Professor at O'Neal Comprehensive Cancer Center at UAB, shared a post on…
Aug 12, 2024, 06:51 | Blog
Remembering Susan Wojcicki, Honoring a Legacy of Leadership and Technological Innovation
In the ever-evolving landscape of Silicon Valley, few figures have left as indelible a mark…
12
All: 198 Posts: 1 - 100
Special Coverage